Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TBXAS1 | P24557 | 9/20 | 0.63 |
| ▸ | PRKCI | P41743 | 1/20 | 0.47 |
| ▸ | CYP19A1 | P11511 | 2/20 | 0.45 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.45 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.45 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.45 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.45 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL311859 | 0.88 | — | — | |
| SCHEMBL9777196 | 0.80 | TBXAS1 (0.85) | TBXAS1PRKCICYP19A1CYP1A2CYP3A4 | |
| SCHEMBL937596 | 0.80 | TBXAS1 (0.95) | TBXAS1PRKCI | |
| SCHEMBL7033762 | 0.80 | TBXAS1 (0.63) | TBXAS1PRKCICYP19A1CYP1A2CYP3A4 | |
| SCHEMBL5858630 | 0.80 | TBXAS1 (0.63) | TBXAS1PRKCICYP19A1 | |
| SCHEMBL6933055 | 0.80 | TBXAS1 (0.63) | TBXAS1PRKCI | |
| Hydrochloric Acid SCHEMBL17746653 | 0.78 | TBXAS1 (0.61) | TBXAS1PRKCICYP19A1 | |
| SCHEMBL2535103 | 0.78 | TBXAS1 (1.00) | TBXAS1 | |
| SCHEMBL939851 | 0.78 | TBXAS1 (1.00) | TBXAS1 | |
| SCHEMBL10247600 | 0.78 | TBXAS1 (1.00) | TBXAS1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220356192-A1 | FUSED 1,4-DIAZEPINES AS BET PROTEIN DEGRADERS | UNIV MICHIGAN REGENTS (US) | 2022-11-10 | — | — | US | disclosed |
| US-11466028-B2 | Fused 1,4-oxazepines as BET protein degraders | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2022-10-11 | — | — | US | disclosed |
| EP-3512855-B1 | FUSED 1,4-OXAZEPINES AS BET PROTEIN DEGRADERS | UNIV MICHIGAN REGENTS (US) | 2022-07-27 | — | — | EP | disclosed |
| CN-110062759-B | Fused 1, 4-oxazepine as BET protein degrading agent | 密执安大学评议会 | 2022-05-24 | — | — | CN | disclosed |
| US-20210284657-A1 | FUSED 1,4-OXAZEPINES AS BET PROTEIN DEGRADERS | UNIV MICHIGAN REGENTS (US) | 2021-09-16 | — | — | US | disclosed |
| EP-3858837-A1 | FUSED 1,4-DIAZEPINES AS BET PROTEIN DEGRADERS | The Regents of The University of Michigan (US) | 2021-08-04 | — | — | EP | disclosed |
| US-10975093-B2 | Fused 1,4-diazepines as BET protein degraders | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2021-04-13 | — | — | US | disclosed |
| US-20210002289-A1 | MONOFUNCTIONAL INTERMEDIATES FOR LIGAND-DEPENDENT TARGET PROTEIN DEGRADATION | UNIV MICHIGAN REGENTS (US) | 2021-01-07 | — | — | US | disclosed |
| EP-3512853-B1 | FUSED 1,4-DIAZEPINES AS BET PROTEIN DEGRADERS | UNIV MICHIGAN REGENTS (US) | 2020-12-23 | — | — | EP | disclosed |
| US-10759808-B2 | Monofunctional intermediates for ligand-dependent target protein degradation | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2020-09-01 | — | — | US | disclosed |
| WO-2018052945-A1 | FUSED 1,4-OXAZEPINES AS BET PROTEIN DEGRADERS | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2018-03-22 | — | — | WO | disclosed |
| WO-2017176958-A1 | MONOFUNCTIONAL INTERMEDIATES FOR LIGAND-DEPENDENT TARGET PROTEIN DEGRADATION | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2017-10-12 | — | — | WO | disclosed |
| US-8093229-B2 | Alkynyl pyrrolo[2,3-d]pyrimidines and related analogs as HSP90-inhibitors | CONFORMA THERAPEUTICS CORPORATION (US) | 2012-01-10 | — | — | US | disclosed |
| US-20090318387-A1 | ALKYNYL PYRROLO[2,3-d]PYRIMIDINES AND RELATED ANALOGS AS HSP90-INHIBITORS | CONFORMA THERAPEUTICS CORPORATION | 2009-12-24 | — | — | US | disclosed |
| US-7544672-B2 | Alkynyl pyrrolo[2,3-d]pyrimidines and related analogs as HSP90-inhibitors | CONFORMA THERAPEUTICS CORPORATION (US) | 2009-06-09 | — | — | US | disclosed |
| EP-1869027-A2 | ALKYNYL PYRROLOPYRIMIDINES AND RELATED ANALOGS AS HSP90-INHIBITORS | Conforma Therapeutics Corporation (US) | 2007-12-26 | — | — | EP | disclosed |
| US-20060223797-A1 | ALKYNYL PYRROLOPYRIMIDINES AND RELATED ANALOGS AS HSP90-INHIBITORS | CONFORMA THERAPEUTICS CORPORATION | 2006-10-05 | — | — | US | disclosed |
| WO-2006105372-A2 | ALKYNYL PYRROLOPYRIMIDINES AND RELATED ANALOGS AS HSP90-INHIBITORS | CONFORMA THERAPEUTICS CORPORATION (US) | 2006-10-05 | — | — | WO | disclosed |
| US-4921862-A | Carbostyril derivatives as combined thromboxane synthetase and cyclic-amp phosphodiesterase inhibitors | SYNTEX (U.S.A.) INC. (US) | 1990-05-01 | — | — | US | disclosed |
| US-4792561-A | ANTICOAGULANTS, CARDIOVASCULAR DISORDERS | SYNTEX (U.S.A.) INC. (US) | 1988-12-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10759808-B2 | Monofunctional intermediates for ligand-dependent target protein degradation | MDM2, CD74, TNFSF10 | TBXAS1 3095/4885PRKCI 3162/4885CYP19A1 2369/4885 |
| US-11466028-B2 | Fused 1,4-oxazepines as BET protein degraders | BRD4, BET1, BRD1 | TBXAS1 2221/4885PRKCI 3389/4885CYP19A1 1360/4885 |
| US-20090318387-A1 | ALKYNYL PYRROLO[2,3-d]PYRIMIDINES AND RELATED ANALOGS AS HSP90-INHIBITORS | HSP90AB2P, HSP90AB1, HSP90AA1 | TBXAS1 574/4885PRKCI 1361/4885CYP19A1 4543/4885 |
| US-20060223797-A1 | ALKYNYL PYRROLOPYRIMIDINES AND RELATED ANALOGS AS HSP90-INHIBITORS | HSP90AB2P, HSP90AB1, HSP90AA1 | TBXAS1 751/4885PRKCI 1236/4885CYP19A1 4557/4885 |
| US-10975093-B2 | Fused 1,4-diazepines as BET protein degraders | BRD4, BRD1, BET1 | TBXAS1 2180/4885PRKCI 3471/4885CYP19A1 2583/4885 |
| US-20210002289-A1 | MONOFUNCTIONAL INTERMEDIATES FOR LIGAND-DEPENDENT TARGET PROTEIN DEGRADATION | MDM2, CD74, TNFSF10 | TBXAS1 3095/4885PRKCI 3162/4885CYP19A1 2369/4885 |
| US-20210284657-A1 | FUSED 1,4-OXAZEPINES AS BET PROTEIN DEGRADERS | BRD4, BET1, BRD1 | TBXAS1 2221/4885PRKCI 3389/4885CYP19A1 1360/4885 |
| US-20220356192-A1 | FUSED 1,4-DIAZEPINES AS BET PROTEIN DEGRADERS | BRD4, BRD1, BET1 | TBXAS1 2180/4885PRKCI 3471/4885CYP19A1 2583/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.